Article
- The EMBO Journal (2003) 22, 1442 - 1450
- doi:10.1093/emboj/cdg133
Subject Categories:
Mdm2 haplo-insufficiency profoundly inhibits Myc-induced lymphomagenesis
Jodi R. Alt1,2, Timothy C. Greiner2, John L. Cleveland3 and Christine M. Eischen1,2
- Eppley Institute for Cancer Research, 987696 University of Nebraska Medical Center, Omaha, NE 68198, USA
- Department of Pathology and Microbiology, 987696 University of Nebraska Medical Center, Omaha, NE 68198 USA
- Department of Biochemistry, St Jude Children's Research Hospital, Memphis, TN 38105, USA
Correspondence to:
Christine M. Eischen, E-mail: ceischen@unmc.edu
Received 21 October 2002; Accepted 27 January 2003; Revised 10 January 2003
Abstract
Mdm2 harnesses the p53 tumor suppressor, yet loss of one Mdm2 allele in Mdm2+/- mice has heretofore not been shown to impair tumor development. Here we report that Mdm2 haplo-insufficiency profoundly suppresses lymphomagenesis in E
-myc transgenic mice. Mdm2+/-E
-myc transgenics had greatly protracted rates of B cell lymphoma development with life spans twice that of wild-type transgenic littermates. Im paired lymphoma development was associated with drastic reductions in peripheral B cell numbers in Mdm2+/-E
-myc transgenics, and primary pre-B cells from Mdm2+/-E
-myc transgenics and Mdm2+/- littermates were extremely susceptible to spontaneous apoptosis. Loss of p53 rescued all of the effects of Mdm2 haplo-insufficiency, indicating they were p53 dependent. Furthermore, half of the lymphomas that ultimately emerged in Mdm2+/-E
-myc transgenics harbored inactivating mutations in p53, and the majority overcame haplo-insufficiency by overexpressing Mdm2. These results support the concept that Mdm2 functions are rate limiting in lymphomagenesis and that targeting Mdm2 will enhance p53-mediated apoptosis, compromising tumor development and/or maintenance.
Keywords:
- apoptosis,
- lymphoma,
- Mdm2,
- Myc,
- p53



